TCR Therapy Market Report 2025

This report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The TCR therapy market size has grown exponentially in recent years. It will grow from $0.18 billion in 2024 to $0.26 billion in 2025 at a compound annual growth rate (CAGR) of 40.3%. The growth in the historic period can be attributed to increasing incidence of cancer, growing interest in immunotherapy, encouraging clinical trial results, sufficient financial support from investors.

The TCR therapy market size is expected to see exponential growth in the next few years. It will grow to $0.87 billion in 2029 at a compound annual growth rate (CAGR) of 35.4%. The growth in the forecast period can be attributed to increase in ongoing clinical trials, the use of innovative technologies in healthcare, expanding application in solid tumors, regulatory support and streamlined approval processes, integration with complementary therapies. Major trends in the forecast period include expansion to solid tumors, next-generation TCR engineering, increasing personalization and neoantigen identification, global collaborations and strategic partnerships, continuous research in immunology and tumor biology.

The rising prevalence of cancer is anticipated to drive the expansion of the TCR therapy market in the foreseeable future. Cancer, a condition characterized by the unchecked proliferation and dissemination of abnormal cells in the body, poses a significant threat as it can infiltrate and damage healthy tissues, compromising organ function and systemic health. This phenomenon is attributed to lifestyle choices, the aging demographic, the widespread issue of obesity, and genetic predispositions. T-cell receptor (TCR) therapy exploits the immune system's capabilities to selectively target and enhance the efficacy of cancer treatment, offering a potentially revolutionary approach to addressing the disease. For example, Macmillan Cancer Support, a healthcare charity based in the UK, projected in October 2022 that the number of cancer cases would increase from 3 million in 2020 to 3.5 million by 2025, 4 million by 2030, and 5.3 million by 2040, underscoring the driving force behind the growth of the TCR therapy market.

Leading players in the TCR therapy sector are embracing a strategic partnership strategy to deliver essential therapies to patients and gain a competitive advantage. Strategic partnerships involve leveraging each other's strengths and resources to achieve mutual benefits and success. For instance, in December 2023, ImmunoScape, a biotechnology company based in the US, collaborated with the Experimental Drug Development Centre (EDDC), a pharmaceutical company in Singapore, to develop novel TCR-based bispecific molecules targeting solid tumors. This collaboration aims to capitalize on ImmunoScape's expertise in systems immunology and computational biology, combined with EDDC's capabilities, to drive research forward and establish a strategic alliance that capitalizes on their respective strengths to expedite the development of more accessible and potentially more efficacious cancer treatments.

In January 2023, AstraZeneca, a pharmaceutical and biotechnology company headquartered in the UK, acquired Neogene Therapeutics Inc. for $320 million, significantly bolstering its presence in the burgeoning field of TCR-T therapy. This acquisition granted AstraZeneca access to cutting-edge technology, valuable expertise, and a shared commitment to advancing new cancer treatments, ultimately aiming to enhance the quality of life for patients across various cancer types. Neogene Therapeutics Inc., a US-based biotechnology company, is dedicated to developing next-generation, fully personalized engineered T-cell therapies for a wide range of cancers.

Major companies operating in the TCR therapy market are Pfizer Inc., Johnson & Johnson Services Inc., Novartis AG, Bristol Myers Squibb Company, GlaxoSmithKline PLC, Gilead Sciences Inc., Bluebird bio Inc., Immunocore Limited, Immatics N.V., Poseida Therapeutics Inc., Fate Therapeutics Inc., Atara Biotherapeutics Inc., Intellia Therapeutics Inc., Precision Biosciences Inc., Takara Bio Inc., Tessa Therapeutics, Adaptimmune Therapeutics plc, Cellectis S.A., Zelluna Immunotherapy AS, Cellular Biomedicine Group Inc., Lion TCR Pte Ltd., TCRCure Biopharma Corp., Asher Biotherapeutics Inc., Be Biopharma Inc., Alaunos Therapeutics Inc., China Immunotech Inc.

North America was the largest region in the TCR therapy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the tcr therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the tcr therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The TCR therapy market consists of revenues earned by entities by providing services such as genetic engineering services, quality control and assurance, clinical trial support, and consulting services. The market value includes the value of related goods sold by the service provider or included within the service offering. The TCR therapy market also includes sales of TCR constructs, genetic modification tools, viral vectors, delivery systems, cell culture media and reagents, patient monitoring tools, and bioinformatics and data analysis tools. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

T-cell receptor (TCR) therapy is a type of immunotherapy that involves modifying a patient's T cells to enhance their ability to detect and combat cancer cells. Primarily utilized in cancer treatment, this therapy aims to leverage the body's immune system to target and eliminate cancerous cells.

TCR therapy encompasses various forms such as infusions, injectables, and other modalities. Infusions typically involve immersing a substance (e.g., herbs, tea leaves, or flavorings) in a liquid (usually hot water) to extract its properties or flavor. This therapy is utilized across multiple conditions including leukemia, lymphoma, myeloma, among others, and is accessible through both online and offline channels. Its end-users span hospital pharmacies, retail pharmacies, and specialty clinics.

The TCR therapy market research report is one of a series of new reports that provides TCR therapy market statistics, including TCR therapy industry global market size, regional shares, competitors with a TCR therapy market share, detailed TCR therapy market segments, market trends and opportunities, and any further data you may need to thrive in the TCR therapy industry. This TCR therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.